Vibeke Strand | Clinical Trials | Best Researcher Award

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology πŸŽ“ and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 πŸ§ πŸ“š. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 πŸ₯πŸ’‰. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 πŸ”¬πŸ§ͺ. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field πŸ§ πŸ‘. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact πŸŒŸπŸ“˜. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib πŸ’ŠπŸ“Š. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies πŸ“πŸ’Ό. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Claudia Omes | Clinical Trials | Best Researcher Award

Claudia Omes | Clinical Trials | Best Researcher Award

Dr Claudia Omes, Fondazione IRCCS Policlinico San Matteo, Italy

Dr. Claudia Omes is a distinguished biologist specializing in reproductive medicine, embryology, and stem cell research. She holds multiple degrees from the University of Pavia and Milan, including a Ph.D. in Bioengineering and Bioinformatics. Dr. Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine at Policlinico β€œSan Matteo,” Pavia, and a Contract Professor at the University of Pavia. She has contributed to pioneering research in cryopreservation, semen analysis, and stem cell biology, with multiple publications in top journals. She is an active member of ESHRE and SIERR. πŸ§¬πŸ”¬πŸ‘©β€πŸ”¬πŸ“š

Publication Profile

Orcid

Qualifications and Certifications

Dr. Claudia Omes is a distinguished expert in bioengineering and bioinformatics, holding a Ph.D. in the field, along with a Postgraduate degree in Microbiology and Virology, both achieved with high honors πŸŽ“. She also holds multiple specialized certifications, including ISO 9001:2008 Certified Auditor in Public Health πŸ… and certifications in clinical embryology and semen analysis 🧬. Her expertise spans across bioengineering, public health, and clinical research, making her a prominent figure in the scientific community. Dr. Omes’ comprehensive academic background and specialized certifications highlight her commitment to advancing healthcare and biotechnology. πŸŒΏπŸ’‘

Research Experience

Dr. Claudia Omes is the Head Biologist and Lab Director at the Center for Reproductive Medicine of Fondazione I.R.C.C.S. Policlinico β€œSan Matteo.” Her pioneering work in human reproduction and embryology has significantly advanced the field. She specializes in cryopreservation of spermatozoa, oocytes, and embryos, as well as in stem cell research and bone tissue engineering. Through her dedication and expertise, Dr. Omes has made notable contributions to reproductive medicine, with a focus on improving fertility treatments and tissue regeneration. Her work continues to shape the future of reproductive science. πŸ§¬πŸ”¬πŸΌπŸ‘©β€πŸ”¬

Awards and Recognition

Dr. Claudia Omes has earned significant recognition in the scientific community. She was awarded the Best Oral Communication in the Biological Field at the II FISSR conference in Riccione (May 24-26, 2012) πŸ…. In 2011, she received the GIC Study Award from the Italian Society of Cytometry at the XXIX National Conference of Cytometry in Salerno πŸŽ–οΈ. Dr. Omes was also honored with the Best Poster award at the 62nd National Congress of SIAI in Verona (September 14-16, 2008) 🎨. These accomplishments showcase her excellence in the fields of cytometry and biological sciences πŸŒ±πŸ”¬.

Research Focus

Dr. Claudia Omes focuses on reproductive biology and male infertility, exploring factors that impact sperm quality and fertility. Her research investigates the role of infections, inflammation, and biomarkers in male fertility, particularly in infertile and oncological patients. She has contributed to studies on the effects of HPV infections (HPV-51 and HPV-52) on sperm quality, the expression of miRNAs in pre-implantation embryos, and the potential of novel diagnostic approaches like calprotectin to screen for male infertility risk. Additionally, Dr. Omes has studied the effects of cancer-induced inflammation on semen quality and the application of stem cells in reproductive medicine. πŸ§¬πŸ‘¨β€πŸ”¬πŸ’‰

Publication Top Notes